[1]李成斐,朱 萍,于 佳,等.益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响[J].陕西中医杂志,2021,(8):1072-1075,1079.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
　LI Chengfei,ZHU Ping,YU Jia,et al.The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway[J].,2021,(8):1072-1075,1079.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.021]
点击复制

益气活血解毒方联合化疗治疗晚期卵巢癌疗效及对患者免疫通路相关靶基因的影响
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年8期
页码:
1072-1075,1079
栏目:
临床研究
出版日期:
2021-08-05

文章信息/Info

Title:
The effect of Yiqi Huoxie Jiedu decoction combined with TC regimen on advanced ovarian cancer and related target genes of immune pathway
作者:
李成斐1 ; 朱 萍1; 于 佳1; 刘俊彦2; 刘叶玲3
(1.海军第九七一医院,山东 青岛 266000; 2.山东第一医科大学附属肿瘤医院,山东 济南250000; 3. 泰安市中心医院,山东 泰安 271000)
Author(s):
LI Chengfei; ZHU Ping; YU Jia; LIU Junyan; LIU Yeling
(Chinese People's Liberation Army Naval Hospital 971,Qingdao 266000,China)
关键词:
卵巢癌;  晚期;  益气活血解毒方;  免疫功能;  免疫通路相关靶基因
Keywords:
Ovarian cancer;  Advanced stage;  Yiqi Huoxie Jiedu decoction;  Immune function;  Immune pathway-related target genes
分类号:
R 737.31
DOI:
DOI:10.3969/j.issn.1000-7369.2020.08.021
文献标志码:
A
摘要:
目的:探讨益气活血解毒方联合TC方案(紫杉醇联合卡铂)对晚期卵巢癌气虚血瘀证疗效及对患者免疫通路相关靶基因的影响。方法:选择108例晚期卵巢癌气虚血瘀证患者为研究对象,以随机数字表法分为对照组(采用TC方案化疗)和观察组(在对照组的基础上联合益气活血解毒方治疗),每组均为54例,两组均治疗两个疗程。比较两组治疗前后中医症状评分、T淋巴细胞亚群细胞水平,比较两组治疗后临床控制率以及免疫通路相关靶基因表达水平,统计两组治疗期间不良反应发生情况。结果:治疗前,两组中医症状评分、CD4+、CD8+、CD4+/CD8+、丝裂原活化蛋白激酶3(MAPK3)、CD40、杀伤细胞免疫球蛋白样受体2DL3(KIR2DL3)、人类淋巴细胞抗原DQA(HLA-DQA)比较,差异无统计学意义(P>0.05); 治疗后,两组中医症状评分、MAPK3、CD40、KIR2DL3、HLA-DQA均比治疗前低(P<0.05),且观察组低于对照组(P<0.05); 治疗后,两组CD4+、CD8+、CD4+/CD8+均比治疗前高(P<0.05),且观察组更高(P<0.05); 治疗后,观察组临床控制率比对照组高(83.33%与64.81%,P<0.05); 两组治疗期间贫血、恶心呕吐、脱发、白细胞降低等Ⅲ和Ⅳ级不良反应发生率相近(P>0.05)。结论:益气活血解毒方联合TC方案用于治疗晚期卵巢癌气虚血瘀证患者,能够改善患者的临床症状,疗效显著,调节机体免疫功能水平及相关免疫通路。
Abstract:
Objective:To explore the effect of Yiqi Huoxie Jiedu decoction combined with TC regimen(paclitaxel combined with carboplatin)on advanced ovarian cancer with Qi deficiency and blood stasis syndrome and its influence on immune pathway-related target genes.Methods:A total of 108 patients with advanced ovarian cancer with Qi deficiency and blood stasis syndrome were selected as the research objects.They were divided into a control group(with TC regimen chemotherapy)and an observation group(on the basis of the control group,combined with Yiqi Huoxie Jiedu decoction)by random number table,and there were 54 cases in each group,and both groups were treated for two courses.The Chinese medicine symptom scores and T lymphocyte subgroup cell levels of the two groups before and after treatmentwere compared,and compared the clinical control rate and the expression levels of immune pathway-related target genes after the two groups,and count the occurrence of adverse reactions during the treatment of the two groups.Results:Before treatment,the two groups of Chinese medicine symptom scores,leukocyte differentiation antigen 4+(CD4+),CD8+,CD4+/CD8+,mitogen-activated protein kinase 3(MAPK3),CD40,killer cell immunoglobulin-like receptor 2DL3(KIR2DL3),human lymphocyte antigen DQA(HLA-DQA)were compared,the difference was not statistically significant(P>0.05),after treatment,the two groups of Chinese medicine symptom scores,MAPK3,CD40,KIR2DL3,HLA-DQA were lower than before treatment(P<0.05),and the observation group is lower than the control group(P<0.05).After treatment,the two groups of CD4+,CD8+,CD4+/CD8+ were higher than before treatment(P<0.05),and the observation group was higher(P<0.05),after treatment,the clinical control rate of the observation group was higher than that of the control group(83.33% vs. 64.81%,P<0.05).The incidence of grade Ⅲ and Ⅳ adverse reactions such as anemia,nausea and vomiting,alopecia,and leukopenia were similar in the two groups during treatment(P>0.05).Conclusion:Yiqi Huoxue Jiedu decoction combined with TC regimen can be used to treat patients with advanced ovarian cancer with Qi deficiency and blood stasis syndrome,which can improve the clinical symptoms of patients with significant curative effect,regulate the body's immune function level and related immune pathways.

参考文献/References:

[1] 姬荣伟,刘秋霞,田亚宁,等.卵巢癌术前新辅助化疗疗效及对组织CA125、CD146、SP70的表达影响[J].陕西医学杂志,2018,47(12):1648-1650,1666.
[2] 习 辉,聂鸿雁,张世凤.热疗联合TC化疗治疗晚期卵巢癌的疗效及对免疫逃逸、远期预后的影响[J].中国性科学,2020,29(8):18-21.
[3] 王沈峰,金 迎,周禄荣,等.益气活血法治疗卵巢癌及对患者血清人附睾蛋白4、间皮素及肿瘤标记物的影响研究[J].陕西中医,2020,41(5):646-649.
[4] 于晓宇,贾英杰.中晚期卵巢癌中医证候特征研究[J].北京中医药,2019,38(8):819-821.
[5] 刘 健,孙增涛,刘 伟,等.益气活血解毒法对肺癌微环境作用探析[J].陕西中医,2018,39(9):1285-1287.
[6] 李 娟,翁洁琼,卢雯平.益气活血解毒方治疗晚期上皮性卵巢癌疗效相关靶基因筛选[J].中国中医药信息杂志,2020,27(4):28-34.
[7] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:361-362.
[8] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(7):739-749.
[9] 蒋林哲,王月华,王立波,等.实时荧光定量PCR检测结肠癌中HER2和TOPOⅡα mRNA的表达[J].现代医学,2020,48(1):26-30.
[10] Boyd MR,Paull KD.Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Development Research,2010,34(2):91-109.
[11] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[12] 钟 亮,刘清壮,蔡茂德.Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J].陕西医学杂志,2020,49(2):193-196.
[13] 周 琴,周 帆,张筱骅.理冲汤加减联合TC方案治疗晚期卵巢癌临床研究[J].新中医,2020,52(9):39-43.
[14] 胡海娟.减毒抑癌汤联合TC方案治疗晚期卵巢癌临床疗效及与T细胞亚群水平关系的研究[J].湖北中医药大学学报,2019,21(6):26-29.
[15] 金银珠,沈 影,韩凤娟.“阳化气,阴成形”:卵巢癌的中医证治[J].天津中医药大学学报,2020,39(4):403-406.
[16] 高珍珍,赵春艳,李立安,等.新辅助化疗在晚期卵巢上皮癌治疗中的研究进展[J].中国急救复苏与灾害医学杂志,2019,14(2):172-174.
[17] 庞海江,许家艳,丁守坤.益气活血解毒方联合西药治疗幽门螺杆菌阳性慢性萎缩性胃炎患者的疗效及对胃蛋白酶原的影响[J].世界中医药,2019,14(1):126-130.
[18] 张 月,李友山,庞 鹤,等.益气活血解毒方联合蚕食法治疗糖尿病足30例疗效观察[J].北京中医药,2020,39(6):539-542.
[19] 史东萍,李 强.益气活血解毒方对肺癌A549/DDP耐药细胞株JAK2-STAT3信号通路的干预作用研究[J].中国中医急症,2018,27(5):757-760.
[20] 袁 慧,郭翠琴,武 芳.益气活血解毒散结法对晚期卵巢癌患者无复发生存时间、生活质量及免疫功能的影响[J].现代中西医结合杂志,2019,28(8):883-886.
[21] 张振华,李 娟,卢雯平.益气活血解毒方治疗晚期卵巢癌有效可能的单核苷酸多态性位点及基因靶点[J].中国医药,2018,13(4):601-605.
[22] 宋晓婕.扶正固肾汤对老年卵巢癌术后患者外周血T淋巴细胞亚群及肿瘤标志物的影响[J].中国老年学杂志,2020,40(10):2078-2081.

相似文献/References:

[1]常丰葛,张 珂,马玉瑶,等.白花蛇舌草提取物对卵巢癌模型大鼠的疗效及对其血清性激素水平的影响*[J].陕西中医杂志,2019,(6):687.
　CHANG Fengge,ZHANG Ke,MA Yuyao,et al.Effect of hedyotis diffusa extract on ovarian cancer model rats and its effect on serum sex hormone levels[J].,2019,(8):687.
[2]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医杂志,2020,(2):223.
　SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(8):223.
[3]王沈峰,金 迎,周禄荣,等.益气活血法治疗卵巢癌及对患者血清人附睾蛋白4、间皮素及肿瘤标记物的影响研究*[J].陕西中医杂志,2020,(5):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
　WANG Shenfeng,JIN Ying,ZHOU Lurong,et al.Yiqi Huoxue method in the treatment of ovarian cancer and effects on serum HE4,SMRP and tumor markers[J].,2020,(8):646.[doi:DOI:10.3969/j.issn.10007369.2020.05.026]
[4]胡天祺,杨梦琪,杨 红,等.益气养阴方对卵巢癌术后患者化疗不良反应及生存质量的影响[J].陕西中医杂志,2021,(4):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
　HU Tianqi,YANG Mengqi,YANG Hong,et al.Effect of Yiqi Yangyin recipe on the adverse reaction effects and quality of life in patients with ovarian cancer undergoing chemotherapy[J].,2021,(8):434.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.007]
[5]王小玉,韩凤娟.基于“天癸-肾阳-命门”学说探究卵巢癌发病机制[J].陕西中医杂志,2021,(9):1261.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.029]
[6]陈双凤,吉亚南.温阳活血方对卵巢癌患者免疫指标及炎性因子的影响[J].陕西中医杂志,2021,(10):1371.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.011]
[7]肖 凌,王 洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医杂志,2021,(12):1696.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[8]刘少璇,李 佳,刘芳媛,等.基于“亢害承制”理论辨析卵巢癌因机证治[J].陕西中医杂志,2022,(7):925.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]
　LIU Shaoxuan,LI Jia,LIU Fangyuan,et al.An analysis of mechanism in ovarian cancer based on the theory of “restraining excessiveness to acquire harmony”[J].,2022,(8):925.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.027]
[9]王 倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医杂志,2024,(8):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]
　WANG Qian,JIANG Siyu,LIU Qianxi,et al.Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer[J].,2024,(8):1048.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.008]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(30471806)
更新日期/Last Update: 2021-08-09